0620/24SCR019-18/R10
Media Highlights
From the 2024 ASCO® Annual Meeting
6
Media Outlet Article / Coverage
Cure Lorbrena Shows Longest Progression-Free Survival in
Advanced NSCLC
Cure Posttreatment Imfinzi Sets New Standard for Small Cell
Lung Cancer
Cure Tagrisso Could Become Standard of Care for Some With
EGFR+ NSCLC
Daily Mail FIVE Revolutionary Cancer Therapies That Will Change The
Lives of NHS Patients From This Year, From a Daily Tablet To
a New 'Smart Bomb'
Daily Mail Incredible Hope For Lung Cancer Patients As Doctors
Reveal New Drugs Are Adding Years To People's Lives
DocWireNews ADRIATIC Trial Shows Survival Benefit of Durvalumab in LS-SCLC
DocWireNews David Spigel, MD, on How the Phase 3 ADRIATIC Trial Changes
the Standard of Care for LS-SCLC
eCancer ASCO 2024: Durvalumab Following Chemoradiotherapy
Improved Survival in Patients with Limited-Stage Small-Cell
Lung Cancer
eCancer Durvalumab After Chemoradiotherapy Improves Survival in
Limited-Stage SCLC
European Pharmaceutical
Review
AstraZeneca Immunotherapy Could Boost Lung Cancer Survival
Express Lung Cancer Wonder Drug Hailed as Study Shows 'Off The
Chart' Survival Benefit
Fierce Pharma ASCO: AstraZeneca's Tagrisso, Imfinzi Break New Ground in
Lung Cancer—with One Standing Ovation
Healio Durvalumab Extends Survival in Limited-Stage Small-Cell
Lung Cancer
Healio Osimertinib Delays Progression 'Way More' Than Hoped in
EGFR-Mutant Lung Cancer
David Spigel, MD
SCRI
Continued ➔
